Skip to content
No results
  • Home
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • About Us
  • Contact Us
The Pharma Data
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press Releases

WuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu

  • The Pharma Data
  • June 10, 2025

WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN…

Read MoreWuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu
  • News

Alnylam Wins EU OK for AMVUTTRA to Treat ATTR-CM

  • The Pharma Data
  • June 10, 2025

Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for…

Read MoreAlnylam Wins EU OK for AMVUTTRA to Treat ATTR-CM
  • News

China CDE Accepts Merck’s Pimicotinib Application for TGCT Treatment

  • The Pharma Data
  • June 10, 2025

Merck’s Pimicotinib Accepted for Priority Review in China, Offering Hope for Patients with TGCT Merck, a prominent global science and technology company, announced a significant milestone in its oncology portfolio…

Read MoreChina CDE Accepts Merck’s Pimicotinib Application for TGCT Treatment
  • Press Releases

Sanofi Speeds Up Beyfortus Shipments Ahead of 2025-2026 RSV Season

  • The Pharma Data
  • June 10, 2025

Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory…

Read MoreSanofi Speeds Up Beyfortus Shipments Ahead of 2025-2026 RSV Season
  • News

FDA Approves Merck’s ENFLONSIA™ to Prevent RSV in Infants

  • The Pharma Data
  • June 10, 2025

FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S.…

Read MoreFDA Approves Merck’s ENFLONSIA™ to Prevent RSV in Infants
  • News

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

  • The Pharma Data
  • June 7, 2025

Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market…

Read MorePharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion
  • News

JCR Pharmaceuticals Celebrates 50 Years with Unique Global Website Launch

  • The Pharma Data
  • June 7, 2025

JCR Pharmaceuticals Celebrates 50 Years of Innovation with Global Website Launch That Reflects Its Expanding Reach and Human-Centric Mission As JCR Pharmaceuticals commemorates its 50th anniversary, the global specialty biopharmaceutical…

Read MoreJCR Pharmaceuticals Celebrates 50 Years with Unique Global Website Launch
  • Press Releases

WHO Unveils Online Training Series to Support Chemical Emergency Preparedness

  • The Pharma Data
  • June 7, 2025

WHO Advances Global Chemical Hazard Preparedness with New Comprehensive Online Training Series In a recent address to the Seventy-eighth World Health Assembly, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World…

Read MoreWHO Unveils Online Training Series to Support Chemical Emergency Preparedness
  • NewsResearch

Otsuka’s Sibeprenlimab Shows Significant Proteinuria Reduction in Phase 3 IgAN Trial

  • The Pharma Data
  • June 7, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with…

Read MoreOtsuka’s Sibeprenlimab Shows Significant Proteinuria Reduction in Phase 3 IgAN Trial
  • News

Vertex Highlights ALYFTREK® Data and Sweat Chloride Goals at European CF Conference

  • The Pharma Data
  • June 7, 2025

Vertex Showcases Robust Clinical Data Supporting ALYFTREK® and the Critical Role of Sweat Chloride Reduction at 2025 European Cystic Fibrosis Conference New findings reinforce the value of CFTR modulation and…

Read MoreVertex Highlights ALYFTREK® Data and Sweat Chloride Goals at European CF Conference
  • News

Sanofi Showcases Rare Disease Pipeline Innovations at ISTH

  • The Pharma Data
  • June 7, 2025

Sanofi Highlights Robust Pipeline of Innovations in Rare Blood Disorders at ISTH 2025 Sanofi is poised to take center stage at the 33rd Congress of the International Society on Thrombosis…

Read MoreSanofi Showcases Rare Disease Pipeline Innovations at ISTH
  • News

EU Approves Fixed-Duration Calquence Regimens for 1st-Line CLL

  • The Pharma Data
  • June 7, 2025

AstraZeneca’s Fixed-Duration Calquence Regimen Gains EU Approval for First-Line Treatment of Chronic Lymphocytic Leukaemia AstraZeneca has received European Union (EU) approval for a fixed-duration combination therapy using its Bruton’s tyrosine…

Read MoreEU Approves Fixed-Duration Calquence Regimens for 1st-Line CLL
PrevNext

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • EmeraNova™ Strengthens Innovation Leadership with Launch of New Accelerator ProgramNovember 5, 2026
  • Global Healthy Living Foundation Highlights Advances in Myositis and Polymyalgia Rheumatica Research at ACR Convergence 2026November 5, 2026
  • Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple MyelomaNovember 5, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.